Upadacitinib effective in patients with RA who failed prior TNF inhibitor therapy
4.9
$ 12.50
In stock
(520)
Product Description
Switching from one JAK inhibitor to another may be beneficial for some RA patients
JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on th
Debate: After methotrexate failure, is JAK inhibitor or biologic next?
Upadacitinib effective in patients with RA who failed prior TNF inhibitor therapy
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Rheumatoid Arthritis – The Complex Arthritis
Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years - ACR Meeting Abstracts
JAK Inhibitors and FDA Warnings: What Arthritis Patients Need to Know
FDA approves Rinvoq for patients with active psoriatic arthritis
Frontiers The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions
Frontiers JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases
The Great Debate': JAK inhibitors vs biologics following methotrexate failure in RA
One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib
When Your Psoriatic Arthritis Treatment Fails
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study - The Lancet
